Uraemic retention and apoptosis: What is the balance for the inflammatory status in uraemia?

European Journal of Clinical Investigation

Volumn 33, Issue 8, 2003, Pages 631-634

  Glorieux, G ^a   Vanholder, R ^a   Lameire, N ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; UREMIC TOXIN;

APOPTOSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INFLAMMATION; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; UREMIA;

APOPTOSIS; HUMANS; IMMUNITY; IMMUNOGLOBULIN LIGHT CHAINS; INFLAMMATION; NEUTROPHILS; SOLUTIONS; TOXINS, BIOLOGICAL; UREMIA;

EID: 0042666954     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01204.x     Document Type: Note

References (29)

1. Cohen G, Rudnicki M, Deicher R, Hörl WH. Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. Eur J Clin Invest 2003;33:669-676.
2. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10(8):1815-23.
3. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001;24(10):695-725.
4. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55(5):1899-911.
5. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003;63(5):1934-43.
6. Haag-Weber M, Mai B, Horl WH. Isolation of a granulocyte inhibitory protein from uraemic patients with homology of beta 2-microglobulin. Nephrol Dial Transplant 1994;9(4):382-8.
7. Haag-Weber M, Mai B, Horl WH. Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 1994;9(12):1769-73.
8. Cohen G, Haag-Weber M, Mai B, Deicher R, Horl WH. Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 1995;6(6):1592-9.
9. Cohen G, Rudnicki M, Schmaldienst S, Horl WH. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant 2002;17(5):879-83.
10. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif 2001;19(2):143-51.
11. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19(1):53-61.
12. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55(2):648-58.
13. Descamps-Latscha B, Goldfarb B, Nguyen AT, Landais P, London G, Haeffner-Cavaillon N et al. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. Nephron 1991;59(2):279-85.
14. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients. a prospective and cross sectional study. Kidney Int 1991;39(2):320-7.
15. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review [editorial]. J Am Soc Nephrol 1993;3(9):1541-54.
16. Davydov L, Cheng JW. The association of infection and coronary artery disease: an update. Expert Opin Invest Drugs 2000;9(11):2505-17.
17. Stenvinkel P, Heimburger O, Jogestrand T, Karnell A, Samuelsson A. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int 1999;55(6):2531-2.
18. van Tellingen A, Grooteman MP, Schoorl M, Bartels PC, Schoorl M, van der PT et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002;62(2):632-8.
19. Kerr JFR, Wyllie AH, Curie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
20. Squier MK, Sehnert AJ, Cohen JJ. Apoptosis in leukocytes. J Leukoc Biol 1995;57(1):2-10.
21. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products.
22. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes
23. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. Hebert MJ, Takano T, Holthofer H, Brady HR. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J Immunol 1996;157(7):3105-15.
24. Savill JS, Henson PM, Haslett C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel 'charge-sensitive' recognition mechanism. J Clin Invest 1989;5:1518-27.
25. Cohen G, Rudnicki M, Walter F, Niwa T, Horl WH. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol 2001;12(6):1264-71.
26. Kettritz R, Falk RJ, Jennette JC, Gaido ML. Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF alpha-mediated apoptosis.
27. Greenlund LJ, Deckwerth TL, Johnson EM Jr. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995;14(2):303-15.
28. Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E et al. Lp (a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999;55(4):1450-61.
29. Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJ. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol 1999;10(1):93-100.